Fundraising Fox

Progentos Therapeutics

Watertown, US · Founded 2023 · 5 known investors

progentos.com ↗

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells. The company targets the significant unmet need for remyelinating treatments that could repair damage caused by MS and potentially restore lost function.

BiotechDeep TechMedical Devices

Founders & leadership

AR
Aleks Radovic-MorenoDirector
DH
Dmitrij HristodorovDirector
DJ
Dan JanneyDirector
CL
Christopher LooseExecutive Officer, Director
CB
Cassidy BlundellDirector
SM
Sanjay MagaviExecutive Officer
MT
Marc-Olivier TurgeonDirector

Investors · 5

Alta PartnersJackson · $1M – $12M
Longwood FundBoston
Mission BiocapitalSan Francisco · $500K
Dolby Family Venturesreported · 2 sourcesSan Francisco
Service Provider CapitalreportedVail

Reported raises · per SEC filings

Form D private placements
▶$68.6MraisedMay 2024 · 39 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Aleks Radovic-MorenoDirector
  • Dmitrij HristodorovDirector
  • Dan JanneyDirector
  • Christopher LooseExecutive Officer, Director
  • Cassidy BlundellDirector
  • Sanjay MagaviExecutive Officer
  • Marc-Olivier TurgeonDirector
Offering amount
$68.6M
Amount sold
$68.6M
First sale
May 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news